USPTO Examiner HILL MYRON G - Art Unit 1671

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19262172RESPIRATORY SYNCYTIAL VIRUS MRNA VACCINE, AND PREPARATION METHOD THEREFOR AND USE THEREOFJuly 2025August 2025Allow200YesNo
19203759SYSTEM FOR PRODUCING AND DELIVERING CONTACTLESS VETERINARY PASSIVE IMMUNIZATIONMay 2025November 2025Allow611NoNo
19053784Mutated Glycoprotein of Vesicular Stomatitis VirusFebruary 2025July 2025Allow510NoNo
19053808Mutated Glycoprotein of Vesicular Stomatitis VirusFebruary 2025July 2025Allow510NoNo
18895059PRE-FUSION RSV F ANTIGENSSeptember 2024February 2026Abandon1720NoNo
18798779RSV RNA MOLECULES AND COMPOSITIONS FOR VACCINATIONAugust 2024May 2025Allow910NoNo
18649981METHODS FOR TREATING, AMELIORATING OR PREVENTING INFECTIONS USING DRUG AND VACCINATION COMBINATION TREATMENTApril 2024January 2025Allow810YesNo
18629504Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024January 2025Allow920NoNo
18629466Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024March 2025Allow1110YesNo
18629579Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024February 2025Allow1110YesNo
18629097Mutated Glycoprotein of Vesicular Stomatitis VirusApril 2024January 2025Allow920NoNo
18610681RNA VACCINES AGAINST INFECTIOUS DISEASESMarch 2024February 2025Allow1111NoNo
18596426PRE-FUSION RSV F ANTIGENSMarch 2024November 2024Abandon910NoNo
18409645PREFUSION RSV F PROTEINS AND THEIR USEJanuary 2024December 2024Allow1110NoNo
18407208SYSTEM FOR DELIVERY OF INACTIVATED PATHOGENS FOR CONTACTLESS PASSIVE IMMUNIZATIONJanuary 2024January 2025Allow1221NoNo
18505534METHODS FOR IMMUNIZING PRE-IMMUNE SUBJECTS AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV)November 2023June 2025Allow1910YesNo
18490287NOROVIRUS S PARTICLE BASED VACCINES AND METHODS OF MAKING AND USING SAMEOctober 2023September 2025Allow2310NoNo
18485625METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINEOctober 2023July 2025Allow2110NoNo
18378021COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCYOctober 2023July 2025Allow2110NoNo
18552107ANTIBODIES TO SARS-COV-2September 2023October 2025Abandon2511NoNo
18463736NEUTRALIZING ANTI-INFLUENZA B ANTIBODIES AND USES THEREOFSeptember 2023February 2025Allow1720NoNo
18356837DIFFERENTIAL COATING OF MICROPROJECTIONS AND MICRONEEDLES ON ARRAYSJuly 2023September 2025Allow2610NoNo
18355601ANTIGEN SPECIFIC IMMUNOTHERAPY FOR COVID-19 FUSION PROTEINS AND METHODS OF USEJuly 2023March 2025Allow1910NoNo
18338612ZIKA VIRUS VACCINEJune 2023August 2025Allow2611NoNo
18335872METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZAJune 2023July 2024Allow1300YesNo
18335874METHODS AND COMPOSITION FOR NEUTRALIZATION OF INFLUENZAJune 2023August 2024Allow1400YesNo
18323215RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAMEMay 2023November 2023Allow640NoNo
18323192RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAMEMay 2023June 2025Abandon2430YesNo
18323185RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAMEMay 2023December 2023Allow730YesNo
18323177RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAMEMay 2023December 2023Allow640NoNo
18323166RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAMEMay 2023September 2023Allow530YesNo
18323209RSV F PROTEIN COMPOSITIONS AND METHODS FOR MAKING SAMEMay 2023May 2025Abandon2430NoNo
18302400RSV-SPECIFIC ANTIBODIES AND FUNCTIONAL PARTS THEREOFApril 2023August 2024Allow1610NoNo
18043442Hemagglutinin Modifications for Improved Influenza Vaccine ProductionFebruary 2023November 2025Allow3310NoNo
18042093COMPOSITIONS AND METHODS FOR VACCINATION OF JUVENILES AGAINSTRESPIRATORY SYNCYTIAL VIRUS INFECTIONFebruary 2023March 2026Abandon3710NoNo
18040523SARS-COV-2 RAPID SEQUENCE-BASED DIAGNOSTIC ASSAY WITH SENSORS OF IMMUNE ACTIVATION AND THE VIRAL MICROBIOTAFebruary 2023March 2026Abandon3710NoNo
18007092Amino Acid Sequence Derived from Sars-Cov-2 and Use ThereofJanuary 2023March 2026Abandon3710NoNo
18003547VACCINE COMBINATION AGAINST REPIRATORY SYNCYTIAL VIRUS INFECTIONDecember 2022February 2026Abandon3810NoNo
18087745MICRONEEDLE CONTAINING INFLUENZA VACCINE AND INFLUENZA VACCINE PATCH CONTAINING THE SAMEDecember 2022December 2025Allow3610NoNo
18068867STABILIZED RSV F PROTEINS AND USES THEREOFDecember 2022October 2024Allow2220NoNo
18082456IMMUNOGENIC COMBINATIONSDecember 2022August 2025Abandon3210NoNo
17927649Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding FragmentsNovember 2022January 2026Allow3821YesNo
17920416IMMUNIZATION AGAINST SARS-COV-RELATED DISEASESOctober 2022March 2026Abandon4101NoNo
17919733RECOMBINANT HUMAN METAPNEUMOVIRUS F PROTEINS AND THEIR USEOctober 2022March 2026Allow4111NoNo
18046743RECOMBINANT RSV WITH SILENT MUTATIONS, VACCINES, AND METHODS RELATED THERETOOctober 2022August 2024Allow2220NoNo
17931629ANTI-RESPIRATORY SYNCYTIAL VIRUS ANTIBODIES, AND METHODS OF THEIR GENERATION AND USESeptember 2022September 2024Allow2401NoNo
17818887MODIFIED RSV F PROTEINS AND METHODS OF THEIR USEAugust 2022March 2025Allow3110NoNo
17816495SARS-COV-2 CHIMERIC VLP VACCINE COMPOSITION, EXPRESSING VECTOR AND USE THEREOFAugust 2022January 2026Abandon4110NoNo
17860833SERUM-FREE SUSPENSION SYSTEM FOR LENTIVIRAL PRODUCTIONJuly 2022March 2025Allow3311YesNo
17848247PRE-FUSION RSV F ANTIGENSJune 2022October 2025Abandon4060YesNo
17848230PRE-FUSION RSV F ANTIGENSJune 2022June 2024Allow2440YesNo
17831928FCRn-Targeted Mucosal Vaccination Against RSVJune 2022March 2024Allow2220NoNo
17736755Identification of inhibitor peptides to bind with N-terminal Spike (S) and nonstructural protein (NSP) sequences of SARS-COV2 B.1.617.2 Delta or Omicron variants alone and combination with drug(s) for targeted antiviral therapyMay 2022September 2025Allow4001YesNo
17674683RESPIRATORY SYNCYTIAL VIRUS (RSV) POLYANHYDRIDE NANOPARTICLE VACCINEFebruary 2022March 2026Allow4910NoNo
17665704NUCLEIC ACID BASED COMBINATION VACCINESFebruary 2022March 2026Allow4960YesNo
17575829CHIMERIC RSV, IMMUNOGENIC COMPOSITIONS, AND METHODS OF USEJanuary 2022November 2024Allow3410NoNo
17626415METHODS FOR GROWING AFRICAN SWINE FEVER VIRUS IN FETAL PORCINE LUNG ALVEOLAR MACROPHAGE CELLSJanuary 2022December 2025Allow4720NoNo
17622468IMMUNOGENDecember 2021September 2025Abandon4501NoNo
17554232AFRICAN SWINE FEVER VACCINEDecember 2021October 2025Abandon4611NoNo
17546835INFLUENZA B VIRUS REPLICATION FOR VACCINE DEVELOPMENTDecember 2021March 2025Allow3911YesNo
17529665Constructs for Enhancing Immune ResponsesNovember 2021April 2025Allow4100NoNo
17594394PROPHYLACTIC TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS INFECTION WITH AN ADENOVIRUS BASED VACCINEOctober 2021May 2025Abandon4310NoNo
17450348STABILIZED SOLUBLE PRE-FUSION RSV F PROTEINSOctober 2021November 2024Allow3710NoNo
17472721Self-assembled protein nanoparticle and its applications thereofSeptember 2021April 2025Abandon4321YesNo
17458136RELAXIN IMMUNOGLOBULIN FUSION PROTEINS AND METHODS OF USEAugust 2021December 2024Allow3930NoNo
17296879NEW GENERATION REGULATABLE FUSOGENIC ONCOLYTIC HERPES SIMPLEX VIRUS TYPE 1 VIRUS AND METHODS OF USEMay 2021August 2025Allow5111NoNo
17289827RSV VIRUS-LIKE PARTICLES AND METHODS OF USE THEREOFApril 2021March 2025Allow4721NoNo
17241957BACTERIOPHAGE COMPOSITIONS FOR TREATING PSEUDOMONAS INFECTIONApril 2021January 2026Allow5741YesNo
17259844RECOMBINANT ROTAVIRUS EXPRESSION SYSTEM AND RECOMBINANT ROTAVIRUSESJanuary 2021August 2024Allow4321NoNo
17134663Utilizing Vaccines to Treat Cancer and Enhance the Success Rate of Cancer ImmunotherapyDecember 2020January 2026Allow6031NoNo
17054104REVERSE PEPTIDE VACCINENovember 2020July 2024Allow4521NoNo
17052707VACCINE COMPOSITIONNovember 2020June 2025Allow5541NoNo
16930079Treatment of human immunodeficiency virus/acquired immunodeficiency syndromeJuly 2020October 2025Abandon6050NoNo
16761869MEANS AND METHOD FOR PRODUCING AND PURIFYING VIRAL VECTORSMay 2020July 2024Allow5131NoNo
16752328COMBINATION OF IMMUNO-ONCOLYTIC VIRUS DRUGS FOR ENHANCING SYSTEMIC IMMUNE RESPONSE AND APPLICATION THEREOFJanuary 2020March 2024Abandon5021NoNo
16620459METHODS FOR PREDICTING THE USEFULNESS OF DISEASE SPECIFIC AMINO ACID MODIFICATIONS FOR IMMUNOTHERAPYDecember 2019June 2024Allow5420YesYes
16500707PROTEIN ANTIGENS AND USES THEREOFOctober 2019January 2025Allow6011NoNo
16483113NASOPHARYNGEAL PROTEIN BIOMARKERS OF ACUTE RESPIRATORY VIRUS INFECTION AND METHODS OF USING SAMEAugust 2019October 2024Allow6031NoNo
16235030VIRUS CAUSING RESPIRATORY TRACT ILLNESS IN SUSCEPTIBLE MAMMALSDecember 2018August 2019Allow710NoNo
16091257VACCINE AGAINST RSVOctober 2018December 2019Allow1410NoNo
15940432METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCESMarch 2018December 2018Allow910NoNo
15795545METHODS AND COMPOSITIONS FOR STABILIZING DRIED BIOLOGICAL MATERIALSOctober 2017February 2019Allow1620YesNo
15796500VIRUS CAUSING RESPIRATORY TRACT ILLNESS IN SUSCEPTIBLE MAMMALSOctober 2017August 2018Allow910NoNo
15548883ANTIBODIES SPECIFIC TO GLYCOPROTEIN (GP) OF EBOLAVIRUS AND USES FOR THE TREATMENT AND DIAGNOSIS OF EBOLA VIRUS INFECTIONAugust 2017December 2018Allow1621NoNo
15638820RSV G PROTEIN SPECIFIC ANTIBODIESJune 2017March 2018Allow820YesNo
15517693METHODS OF TREATING RSV INFECTIONSApril 2017September 2019Allow3020YesNo
15327142THERMOSTABLE FREEZE DRIED ROTAVIRUS VACCINE FORMULATION AND PROCESS TO PREPARE THEREOFJanuary 2017August 2019Allow3120NoNo
15327102THERMOSTABLE SPRAY DRIED ROTAVIRUS VACCINE FORMULATION AND PROCESS THEREOFJanuary 2017September 2019Allow3220NoNo
15383578VIRAL VECTORS AND THEIR USE IN THERAPEUTIC METHODSDecember 2016September 2019Allow3221NoNo
14913879METHOD OF DETERMINING RESISTANCE TO INFLUENZA VIRUSFebruary 2016January 2018Allow2320YesNo
14890994VACCINES FOR DISEASES CAUSED BY VIRUSES OF THE FAMILY OF REOVIRIDAENovember 2015November 2017Allow2421YesNo
14815131RESPIRATORY SYNCYTIAL VIRUS WITH A GENOMIC DEFICIENCY COMPLEMENTED IN TRANSJuly 2015September 2017Allow2621YesNo
14553957Virus Causing Respiratory Tract Illness in Susceptible MammalsNovember 2014December 2015Allow1320NoNo
14401758Influenza Vaccine ConstructsNovember 2014December 2016Allow2511NoNo
14387476Epitope-Scaffold Immunogens Against Respiratory Syncytial Virus (RSV)September 2014May 2017Allow3221YesNo
14359291RSV G PROTEIN SPECIFIC ANTIBODIESMay 2014March 2017Allow3421YesNo
14270237METAPNEUMOVIRUS STRAINS AND THEIR USE IN VACCINE FORMULATIONS AND AS VECTORS FOR EXPRESSION OF ANTIGENIC SEQUENCESMay 2014February 2016Allow2110NoNo
14161430INFLUENZA B VIRUSES HAVING ALTERATIONS IN THE HEMAGGLUTININ POLYPEPTIDEJanuary 2014February 2015Allow1210NoNo
14009049NUCLEIC ACID CONSTRUCT COMPRISING NUCLEIC ACID DERIVED FROM GENOME OF HEPATITIS C VIRUS OF GENOTYPE 1B, HEPATITIS C VIRUS GENOME-REPLICATING CELLS TRANSFECTED WITH THE SAME, AND METHOD FOR PRODUCING INFECTIOUS HEPATITIS C VIRUS PARTICLESSeptember 2013August 2015Allow2310NoNo
14026567ANTHRAX AND SMALL POX REPLIKINS AND METHODS OF USESeptember 2013October 2015Allow2511NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HILL, MYRON G.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
2
Examiner Affirmed
0
(0.0%)
Examiner Reversed
2
(100.0%)
Reversal Percentile
91.5%
Higher than average

What This Means

With a 100.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.

Strategic Value of Filing an Appeal

Total Appeal Filings
24
Allowed After Appeal Filing
8
(33.3%)
Not Allowed After Appeal Filing
16
(66.7%)
Filing Benefit Percentile
50.7%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner HILL, MYRON G - Prosecution Strategy Guide

Executive Summary

Examiner HILL, MYRON G works in Art Unit 1671 and has examined 158 patent applications in our dataset. With an allowance rate of 94.9%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 43 months.

Allowance Patterns

Examiner HILL, MYRON G's allowance rate of 94.9% places them in the 84% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by HILL, MYRON G receive 2.43 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by HILL, MYRON G is 43 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +3.7% benefit to allowance rate for applications examined by HILL, MYRON G. This interview benefit is in the 26% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 31.0% of applications are subsequently allowed. This success rate is in the 62% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 56.8% of cases where such amendments are filed. This entry rate is in the 83% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 0.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 1% percentile among all examiners. Note: Pre-appeal conferences show limited success with this examiner compared to others. While still worth considering, be prepared to proceed with a full appeal brief if the PAC does not result in favorable action.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 90.9% of appeals filed. This is in the 83% percentile among all examiners. Of these withdrawals, 65.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 48.4% are granted (fully or in part). This grant rate is in the 44% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 20.3% of allowed cases (in the 98% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.7% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.